Advertisement
UK markets close in 3 hours 9 minutes
  • FTSE 100

    8,118.53
    +39.67 (+0.49%)
     
  • FTSE 250

    19,805.34
    +203.36 (+1.04%)
     
  • AIM

    754.69
    +1.57 (+0.21%)
     
  • GBP/EUR

    1.1665
    +0.0008 (+0.07%)
     
  • GBP/USD

    1.2510
    -0.0001 (-0.01%)
     
  • Bitcoin GBP

    51,452.38
    +288.39 (+0.56%)
     
  • CMC Crypto 200

    1,387.44
    -9.10 (-0.65%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.36
    +0.79 (+0.95%)
     
  • GOLD FUTURES

    2,355.50
    +13.00 (+0.55%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,051.27
    +133.99 (+0.75%)
     
  • CAC 40

    8,041.97
    +25.32 (+0.32%)
     

Exploring Collaboration between Pfizer and Sangamo Therapeutics

Exploring Collaboration between Pfizer and Sangamo Therapeutics

On January 3, 2018, Pfizer (PFE) and Sangamo Therapeutics (SGMO) announced a collaboration for developing a potential gene therapy. ALS (or Lou Gehrig’s disease) and FTLD are neurodegenerative disorders caused by mutations in the C9ORF72 gene.